Literature DB >> 16916137

Clinical experience with risperidone and memantine in the treatment of Huntington's disease.

Eylem Sahin Cankurtaran1, Elvan Ozalp, Haldun Soygur, Aysegul Cakir.   

Abstract

We described a 32-year-old woman with Huntington's disease (HD) who presented with severe chorea, psychosis and cognitive abnormalities. We started risperidone at 2 mg p.o./d and increased to 4 mg p.o./d after six weeks. Psychotic and motor symptoms were markedly improved. Since there was no change in cognitive functions, we added memantine at 5 mg p.o./d and gradually increased the dose to 20 mg p.o/d after five weeks. We continued risperidone and memantine for nearly six months. The patient did not show any progression of cognitive symptoms or motor abnormalities. We did not observe any psychotic symptoms.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16916137      PMCID: PMC2569572     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  6 in total

1.  Risperidone in chorea and psychosis of Huntington's disease.

Authors:  A Kemal Erdemoglu; C Boratav
Journal:  Eur J Neurol       Date:  2002-03       Impact factor: 6.089

2.  Dopaminergic neurotoxicity of homocysteine and its derivatives in primary mesencephalic cultures.

Authors:  I Heider; V Lehmensiek; Th Lenk; Th Müller; A Storch
Journal:  J Neural Transm Suppl       Date:  2004

3.  Effectiveness of risperidone in Huntington chorea patients.

Authors:  C Dallocchio; C Buffa; C Tinelli; P Mazzarello
Journal:  J Clin Psychopharmacol       Date:  1999-02       Impact factor: 3.153

Review 4.  Neurobiology of Huntington's disease.

Authors:  A H Sharp; C A Ross
Journal:  Neurobiol Dis       Date:  1996-02       Impact factor: 5.996

5.  Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial.

Authors:  Philip D Harvey; Jonathan Rabinowitz; Marielle Eerdekens; Michael Davidson
Journal:  Am J Psychiatry       Date:  2005-10       Impact factor: 18.112

6.  Cognitive changes in patients with Huntington's disease (HD) and asymptomatic carriers of the HD mutation--a longitudinal follow-up study.

Authors:  Jurgen Lemiere; Marleen Decruyenaere; Gery Evers-Kiebooms; Erik Vandenbussche; Rene Dom
Journal:  J Neurol       Date:  2004-08       Impact factor: 4.849

  6 in total
  16 in total

1.  Psychosis with Huntington's disease: role of antipsychotic medications.

Authors:  Jonathan Ding; Amin Muhammad Gadit
Journal:  BMJ Case Rep       Date:  2014-08-19

Review 2.  Huntington's Disease-Update on Treatments.

Authors:  Kara J Wyant; Andrew J Ridder; Praveen Dayalu
Journal:  Curr Neurol Neurosci Rep       Date:  2017-04       Impact factor: 5.081

Review 3.  Treatment of Huntington's disease.

Authors:  Samuel Frank
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 4.  Advances in the pharmacological management of Huntington's disease.

Authors:  Samuel Frank; Joseph Jankovic
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

Review 5.  Symptomatic treatment of Huntington disease.

Authors:  Octavian R Adam; Joseph Jankovic
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

6.  Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease.

Authors:  Samuel Frank
Journal:  Neuropsychiatr Dis Treat       Date:  2010-10-05       Impact factor: 2.570

7.  State-of-the-art pharmacological approaches to reduce chorea in Huntington's disease.

Authors:  Jessie S Gibson; Daniel O Claassen
Journal:  Expert Opin Pharmacother       Date:  2021-02-08       Impact factor: 4.103

Review 8.  A selective review of glutamate pharmacological therapy in obsessive-compulsive and related disorders.

Authors:  Marco A Grados; Elizabeth B Atkins; Gabriela I Kovacikova; Erin McVicar
Journal:  Psychol Res Behav Manag       Date:  2015-04-28

Review 9.  Current Pharmacological Approaches to Reduce Chorea in Huntington's Disease.

Authors:  Emma M Coppen; Raymund A C Roos
Journal:  Drugs       Date:  2017-01       Impact factor: 9.546

Review 10.  Six psychotropics for pre-symptomatic & early Alzheimer's (MCI), Parkinson's, and Huntington's disease modification.

Authors:  Edward C Lauterbach
Journal:  Neural Regen Res       Date:  2016-11       Impact factor: 5.135

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.